Parschauer Karah Herdman sold $47K of RARE
Parschauer Karah Herdman (EVP and Chief Legal Officer) sold 1,900 shares of Ultragenyx Pharmaceutical Inc. (RARE) at $24.92 on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific open-market sale details (shares, price, total value) by the EVP and Chief Legal Officer, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale, but the 10b5-1 structure and modest dollar value suggest limited incremental trading edge.
What to watch
The sale size ($47.3k) is relatively small versus typical institutional flows, and the filing does not provide any new operational or financial guidance.
Background
The article is a SEC Form 4 insider transaction disclosure for Ultragenyx Pharmaceutical Inc. (RARE).
Ticker impact
Ultragenyx (RARE) disclosed an EVP and Chief Legal Officer open-market sale of 1,900 shares at $24.92 on 2026-08-03 under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely muted and short-lived.
Form 4 insider sales are common and the filing explicitly states a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.
Market effects
No clear sector read-through; this is company-specific insider transaction disclosure.
None indicated.
None indicated.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can coincide with management caution, so traders may still watch for follow-on disclosures.
Key entities
- issuerUltragenyx Pharmaceutical Inc.
RARE, the company that filed the Form 4 insider transaction.
- insiderParschauer Karah Herdman
EVP and Chief Legal Officer who sold 1,900 shares under a 10b5-1 plan.